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Abstract
Myocyte apoptosis is central to myocardial dysfunction following ischemia/reperfusion (I/R) and 
during the transition from hypertrophy to heart failure. Focal adhesion kinase (FAK), a non-
receptor tyrosine kinase regulates adhesion-dependent survival signals and unopposed FAK 
activation has been linked to tumor development. We previously showed that conditional 
myocyte-specific deletion of FAK (MFKO) in the adult heart did not affect basal cardiomyocyte 
survival or cardiac function but led to dilated cardiomyopathy and heart failure following pressure 
overload. In the present study, we sought to determine if FAK functions to limit stress-induced 
cardiomyocyte apoptosis. We reasoned that (I/R), which stimulates robust apoptotic cell death, 
might uncover an important cardioprotective function for FAK. We found that depletion of FAK 
markedly exacerbates hypoxia/re-oxygenation-induced cardiomyocyte cell death in vitro. 
Moreover, deletion of FAK in the adult myocardium resulted in significant increases in I/R-
induced infarct size and cardiomyocyte apoptosis with a concomitant reduction in left ventricular 
function. Finally, our results suggest that NF-κB signaling may play a key role in modulating 
FAK-dependent cardioprotection, since FAK inactivation blunted activation of the NF-κB survival 
signaling pathway and reduced levels of the NF-κB target genes, Bcl2 and Bcl-xl. Since the 
toggling between pro-survival and pro-apoptotic signals remains central to preventing irreversible 
damage to the heart, we conclude that targeted FAK activation may be beneficial for protecting 
stress-dependent cardiac remodeling.
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1. Introduction
Obstruction of blood flow to the heart limits myocyte oxygen and nutrient supply and 
induces programmed (apoptotic) and un-programmed (necrotic) cell death, both important 
causal components of myocardial infarction and heart failure [1–6]. Apoptosis can be 
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initiated by extrinsic (receptor-mediated) and intrinsic pathways (due to mitochondrial 
dysfunction), both of which ultimately lead to activation of the caspase family of proteases, 
which cleave DNA and multiple contractile and cytoskeletal proteins. Although the 
initiation of apoptosis was originally thought to be irreversible, studies now indicate that 
apoptotic cells (unlike necrotic cells) can actually be salvaged by activation of pro-survival 
signaling cascades [2,6–9]. This is likely because of the fact that apoptosis is characterized 
by maintenance of plasma membrane integrity until late in the process unlike necrosis which 
leads to early irreversible disintegration of the plasma membrane. Therefore, understanding 
the precise signaling pathways involved in the regulation of cardiomyocyte survival will be 
important for future development of agents that could be used to treat ischemia-induced 
myocardial dysfunction.
Integrins are transmembrane receptors that mediate cell attachment to extracellular matrix 
(ECM), a critical event for numerous cell responses including cell migration, differentiation, 
proliferation, and protection from apoptosis [10]. In addition to acting as contact points for 
cell attachment, integrin engagement leads to induction of intracellular signals that serve to 
integrate diverse extrinsic cues from growth factor and cytokines receptors. The finding that 
deletion of β1 integrin in adult hearts leads to dilated cardiomyopathy and concomitant heart 
failure [11,12] underscores the possibility that defects in integrin signaling may play a direct 
role in regulating cardiomyocyte survival.
FAK is a non-receptor protein tyrosine kinase, which is strongly and rapidly activated by all 
β1, β3 or β5 containing integrins, and its activation is considered central to integrin-
dependent signal transduction [13]. In some, but not all cell types, FAK stimulates activation 
of the pro-survival kinases, ERK and AKT, and in these cells, FAK inactivation leads to 
apoptosis [14–17]. We recently reported that ventricular myocyte-specific deletion of FAK 
in the adult heart did not affect basal cardiomyocyte survival or cardiac function [18]. 
However, prolonged transverse aortic constriction (TAC) in mice with cardiac-restricted 
FAK deletion led to dilated cardiomyopathy and heart failure. Several studies indicate that 
the switch from hypertrophy to cardiac failure may involve activation of apoptotic pathways. 
For instance, aortic banding of mice with heart-restricted overexpression of Gαq, result in 
dilated cardiomyopathy accompanied by cellular apoptosis, and either overexpression of the 
anti-apoptotic protein, Nix or administration of caspase inhibitors significantly reversed 
myocardial dysfunction in these mice [19–21]. Although we did not detect significant 
cardiomyocyte apoptosis in the banded FAK null hearts [18], we could not rule out a 
cardioprotective effect of FAK in this setting since apoptosis induced by chronic TAC is 
spatially diffuse and occurs over a prolonged time scale.
In the present study, we explored the possibility that the stress induced by I/R, which results 
in robust localized apoptotic and necrotic cell death [1,22] might uncover an important 
function for FAK as a cardioprotective signaling molecule. Herein, we found that oxidative 
stress induced more pronounced apoptotic cell death in FAK null cardiomyocytes than in the 
FAK-containing cardiomyocytes using both in vitro and in vivo model systems. Subsequent 
mechanistic studies revealed that FAK was necessary for NF-κB-induced survival signaling 
following I/R injury. We conclude that targeted FAK activation may be beneficial for 
protecting I/R-induced myocardial dysfunction.
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2. Materials and methods
2.1. Antibodies and chemicals
The FAK antibody was purchased from Upstate Biotechnology, Inc, the antibodies directed 
towards phosphorylated ser536 NF-κB (p65), phosphorylated ser32/36 IκBα IκBα and Bcl-xl 
were purchased from Cell Signaling Technology, the phosphorylated Tyr 397 FAK antibody 
was purchased from BioSource, the α-tubulin antibody was purchased from Sigma, the Bcl2 
antibody was purchased from Upstate and the NF-κB and troponin T antibodies were a 
generous gift from Dr. Craig Selzman (CCBC, UNC-CH) and Nadia Malouf (Department of 
Pathology and Laboratory Medicine, UNC-CH) respectively.
2.2. In vitro hypoxia/re-oxygenation (Hypox/Reox)
FAK null and FAK containing ventricular cardiomyocytes expressing GFP under the control 
of the β-MHC promoter were isolated from fakflox/floxnkx2-5Cre/wtβMHCgfp (FAK−/−/
βMHCgfp) and littermate control fakflox/floxnkx2-5wt/wtβMHCgfp (FAK+/+/βMHCgfp) hearts 
respectively, and cultured as described previously [23]. Cardiac cells were plated at cell 
density of 10,000 cells on fibronectin (FN)-coated 96-well plates and cultured for 12 h in 
serum medium. Viable attached cardiomyocytes (identified by nuclear GFP labeling and 
verified by Trypan Blue dye exclusion) were counted in 4 fields at 10× magnification. Prior 
to experimentation, serum-containing media was replaced with glucose- and serum-free 
medium in the hypoxic group, which were then placed in a hypoxia chamber set to confer an 
atmosphere of 1% O2, 5% CO2, and 95% N2. Cells were incubated for 2 h prior to re-
oxygenation for an hour. Cells were rinsed briefly with PBS, fixed with 4% PFA for 20 min 
at 25 °C and counted as described above. Cell death was expressed as a ratio of the number 
of GFP positive cells counted after Hypox/Reox to that before Hypox/Reox. Finally, 
cardiomyocyte apoptosis in response to Hypox/Reox was determined by calculating the 
percentage of viable cardiomyocytes (spread GFP positive cells that excluded Trypan Blue) 
in Hypox/Reox compared to the viable cardiomyocytes in the normoxia group.
For biochemical analysis of FAK phosphorylation following Hypox/Reox, neonatal (P0) rat 
cardiomyocytes were isolated using a commercially available kit from Worthington 
according to the vendor’s instructions. Isolated cardiomyocytes were plated on 0.1% gelatin-
coated 60 mm dishes with 100 μM BrDu to prevent fibroblast contamination. The cells were 
cultured in heart medium and then exposed to normoxia (2.5 h) or Hypox/Reox (2 h and 15 
min or 2 h and 30 min). Cell lysates were prepared and subjected to western analysis as 
described below.
2.3. Mice
fakflox/flox or fakflox/wt (genetic control) mice with FAK-containing cardiomyocytes, 
fakflox/flox/mlc2vCre/wt (MFKO) mice with FAK-deficient cardiomyocytes, FAK+/+/
βMHCgfp mice with GFP-positive, FAK-containing cardiomyocytes and FAK−/−/βMHCgfp 
mice with GFP-positive, FAK-deficient cardiomyocytes were generated and genotyped as 
described previously [16,18,23]. All mice used for the I/R experiments were backcrossed to 
the C57black6 background at least 8 generations prior to subsequent breeding.
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All animals were maintained in a facility accredited by the Association for the Assessment 
and Accreditation of Laboratory Animal Care International (AALACI) according to the 
Institutional Animal Care and Use Committee (IACUC)-approved guidelines. All surgical 
procedures were approved by the AALACI-accredited IACUC at the University of North 
Carolina at Chapel Hill, Chapel Hill, NC.
2.4. Coronary artery ligation
Briefly, aged matched genetic control and MFKO male and female mice were anesthetized 
to perform a left thoracotomy under mechanical ventilation. Mice were anesthetized using 
isoflurane from an automated and calibrated device. The body temperatures of the mice 
were maintained by a heated surgical platform and body temperature was monitored using a 
rectal sensor during the surgical procedure. ECG electrodes were attached to the mouse (in 
the supine position) and a frontal plane 3-lead ECG was also recorded during the surgical 
procedure. The left anterior descending (LAD) coronary artery was occluded near its origin 
with a 6–0 suture for 30 min to produce transient ischemia. Consistent elevation of the ST 
segment was observed in lead II tracings following occlusion of the LAD coronary vessel 
and in each case removal of the suture was followed by a concomitant depression of this 
segment. After 24 h of reperfusion, the LAD was re-occluded and the right carotid artery 
was cannulated to allow injection of 1 ml of KCL (40 mEq/L) followed by 1 ml of 1% 
Evan’s Blue dye (in PBS) for identification of the area at risk (AR). The hearts were excised 
and rinsed briefly in PBS. The atria were removed and ventricles were sliced transversely 
into 6×1 mm thick slices using an acrylic heart matrix. Starting from the base of the heart, 
slice 1 was used to obtain DNA for FAK recombination PCR, slice 2 was used for RNA 
analysis, slice 3 was used for protein analysis, and slices 4 and 5 were utilized for infarct 
size measurements. Briefly, slices 4 and 5 were incubated with 1% triphenyltretrazolium 
chloride (TTC, pH 7.4 in phosphate buffer) at 37°C for 30 min. After immersion in TTC, the 
slices were fixed in 4% PFA and infarct size was quantified as described below.
2.5. Quantification myocardial infarction
Slices 4 and 5 stained with Evan’s Blue dye and TTC were photographed and the images 
were used to quantify I/R-induced myocardial infarction using the software, NIH Image J. 
The Evan’s Blue stained area defined the perfused area whereas; the Evan’s Blue unstained 
area defined the area at risk (AR). The area lacking the red TTC staining within the AR was 
considered as the infarct area (I). Relative AR (RAR) was considered as the AR expressed 
as percentage of the total slice area (T), and the relative infarct area (RI) was calculated by 
dividing I by the RAR. Both the surgeon and the two independent evaluators of infarct size 
were blinded to mouse genotypes.
2.6. Heart function
Echocardiography was performed prior to I/R injury as described previously [18] to 
determine the baseline heart function and ventricular dimensions in the experimental groups. 
We performed hemodynamic measurements after 24 h of reperfusion using a 1.0 F catheter 
tip micromanometer (Millar PVR-1035). Following calibration, the catheter (connected to a 
Powerlab 40/3 data acquisition box; ADInstruments) was inserted through the right carotid 
artery and into the left ventricular cavity of anesthetized mice. We analyzed the first 
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derivative of left ventricular pressure (dP/dT) using PVAN 3.6 software (Millar) following 
administration of a saline bolus of 2 μl of 15% NaCl via the left subclavian vein.
2.7. Apoptosis
In some mice, slices 4 and 5 (procured as described above) were fixed in 4% PFA, 
embedded in paraffin, sectioned, and processed to detect DNA strand breaks by the TUNEL-
reaction using a commercially available kit (Roche, 12156792910) according to the 
manufacturer’s instructions. IHC was performed on the same slides for troponin T to label 
cardiomyocytes as described previously [18]. TUNEL positive cardiomyocyte nuclei were 
counted within the left ventricle juxtaposed to the necrotic area (delineated by regions 
devoid of troponin T immunoreactivity).
2.8. Western blot analysis
Cell and tissue lysates (procured as described above) were prepared as previously described 
[23]. Antibodies for phosphorylated Tyr 397FAK, FAK, phosphorylated Ser 536 NF-κB (p65), 
NF-κB (p65), phosphorylated Ser32/36 IκBα, IκBα Bcl2, Bcl-xl and α-tubulin were used at a 
1:1000 dilution for immunoblot analysis as previously described [23].
2.9. Semi-quantitative reverse transcription-PCR (RT-PCR)
Heart slice 2 (procured as described above) from the experimental mice were snap-frozen in 
liquid nitrogen. RNA was extracted using TRIzol reagent (Invitrogen) and cDNA was 
obtained by reverse transcription using a commercially available kit (iScript; Bio-Rad). 
Semi-quantitative RT-PCR analysis of the cDNA was carried out using 1 μl of diluted 
cDNA (1:2) as a template, PCR reaction mix Jumpstart (Sigma) and previously published 
primers and cycling conditions for Bcl2 [23] and Bcl-xl [24]. The primers used for 18S were 
forward, AGAAACGGCTACCACATCCA and reverse, 
CTCGAAAGAGTCCTGTATTGT.
2.10. Statistical analysis
All replicate data are expressed as mean and standard error of mean (SEM). Statistical 
significance was tested using the two-tailed, unpaired Students’ t test or one-way ANOVA 
followed by post-hoc Tuckey test using commercial software.
3. Results
3.1. Hypoxia-reperfusion induced cell death is enhanced in FAK null cardiomyocytes
The enhanced systolic dysfunction and rapid progression to cardiac failure observed 
following persistent pressure overload in hearts with myocardial-restricted deletion of FAK 
indicated the possibility that FAK might play a cardioprotective role in this setting. Since 
previous reports indicated that hypoxia induced transient activation of FAK in both cultured 
myocytes and neurons [25,26] we sought to determine whether FAK might function to 
promote cell survival under ischemic conditions. We first employed an in vitro model of I/R 
(i.e. hypoxia/serum and glucose deprivation followed by re-oxygenation; Hypox/Reox) in 
FAK containing and FAK null cardiomyocytes to determine whether FAK plays a critical 
role in protecting cardiomyocytes from apoptosis associated with this process. To this end, 
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cardiomyocytes were isolated from E17.5 FAK−/−/βMHCgfp and littermate control FAK+/+/
βMHCgfp mice, in which myocytes can be identified by nuclear GFP expression. As 
previously reported, both FAK+/+/βMHCgfp and FAK−/−/βMHCgfp cardiomyocytes exhibit 
comparable well-defined sarcomeric actin organization when plated on fibronectin matrix 
(Fig. 1A. Left) [23]. We next subjected these cultured cells to low (1% O2) for 2 h followed 
by re-oxygenation in serum- and glucose-containing medium for an hour to stimulate 
Hypox/Reox-dependent apoptosis [27]. Approximately 25% of the FAK+/+/βMHCgfp 
cardiomyocytes died following this treatment (Fig. 1A. middle and right panels, Fig. 1B). 
However, Hypox/Reox-induced cell death was significantly greater (approximately 60%) in 
comparably treated FAK−/−/βMHCgfp cardiomyocytes. Importantly, we found that Hypox/
Reox induced rapid activation of FAK in cultured cardiomyocytes (Fig. 1C), confirming and 
extending previous reports that hypoxia alone induced transient activation of FAK in both 
cultured myocytes and neurons [26]. Since FAK activity is not necessary for survival of 
cardiomyocytes under basal conditions [18,23], we speculate that hypoxia and Hypox/Reox-
induced activation of FAK may reflect an adaptive response to stress, and that FAK may 
play a critical role in promoting cardiomyocyte survival under these conditions.
3.2. Cardiac-restricted deletion of FAK exacerbates I/R-induced myocardial infarction in 
vivo
We next examined whether FAK also functions as a cardioprotective signal transducer in 
vivo. To this end, we bred fakflox/flox mice [16] to mlc2vCre/wt mice [28] to generate the 
MFKO (fakflox/flox/mlc2vCre/wt) mice that were deficient in ventricular FAK from 13 weeks 
post-natal onwards [18]. Corroborating our previous findings that global cardiac structure 
and function is preserved in MFKO hearts [18], the cohort of MFKO and fakflox/flox/
mlc2vwt/wt (genetic control) mice used for the present studies exhibited no significant 
differences at baseline in heart rate, ventricular chamber and wall dimensions, ejection 
fraction, or fractional shortening as assessed by echocardiography (Table 1).
We next subjected the genetic control and MFKO mice to 30 min of ischemia followed by 
24 h of reperfusion (induced by transient ligation of the LAD coronary artery) and assessed 
infarct size and myocardial function. Although, the non-perfused region or relative area at 
risk (RAR; non-blue/total area in Fig. 2A) was comparable between the two groups (MFKO; 
32.6±2.9% and genetic controls; 33.5±5.8%, Fig. 2B), the MFKO mice exhibited a 
significantly increased relative infarct size (RI; ratio of the non-viable white area to the 
RAR; Fig. 2A) compared to the genetic control mice (36.1±7.3% vs. 14.4±3.1%; p<0.05; 
n=6 for each genotype, Fig. 2C). Importantly, we observed comparable infarcts in our two 
groups of control mice [genetic control and fakwt/wt/mlc2vCre/wt (Cre control)], indicating 
that neither expression of the Cre recombinase, nor haplo-insufficiency of Mlc2v influenced 
this injury response (Fig. 2C). Mice were also analyzed for myocardial function by cardiac 
catheterization. As shown in Table 2, both LVESP and contractility were significantly 
reduced in the I/R MFKO group when compared to either the I/R genetic controls or the 
sham MFKO groups, in strong support of the thesis that FAK plays a critical role in 
mediating cardioprotection following an ischemic insult.
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3.3. FAK deficiency enhances I/R-induced apoptosis
We next examined whether the increased infarct size in the MFKO hearts was accompanied 
by enhanced apoptosis within the AR. Indeed, although baseline levels of apoptosis were 
low and not significantly different between the two experimental groups (data not shown), 
we observed a significantly higher number of TUNEL positive cardiomyocyte nuclei in the 
region juxtaposed to the infarct zone in the left ventricle of the MFKO mice compared to the 
genetic control mice following I/R (Figs. 3A–C).
3.4. Activation of the NF-κB survival pathway is attenuated in MFKO hearts
FAK has been recently shown to modulate activation of pro-survival signals induced by NF-
κB [29–31]. Since cardiac NF-κB levels progressively increase following I/R and some 
studies indicate that NF-κB protects cardiomyocytes from I/R-induced apoptosis [32–34], 
we sought to examine the activity of this pathway in the MFKO hearts. We first examined 
the level of phosphorylated inhibitor κB (IκB), since FAK has previously been shown to be 
necessary for receptor-dependent activation of the IκB kinase (IKK) As shown in Fig. 4A, 
the level of phosphorylated Ser32/36 IκBα in the MFKO hearts was markedly reduced in 
comparison to the genetic controls. Accordingly, a concomitant increase in IκB protein and 
decrease in NF-κB activity (as assessed by phosphorylation of Ser536) were also detected in 
the post I/R MFKO hearts in comparison to the post I/R control hearts (Figs. 4A, B).
To confirm and extend the observation that NF-κB-dependent signaling is defective in 
MFKO hearts, we next explored the expression levels of the NF-κB target genes, Bcl2 and 
Bcl-xl. As shown in Figs. 4C–E, we found that both the message and protein levels of the 
anti-apoptotic genes, Bcl2 and Bcl-xl, which can be induced by NF-κB-dependent signaling 
[29,35,36], were significantly reduced in post I/R MFKO in comparison to the genetic 
controls. Collectively, these studies support the possibility that FAK may promote cell 
survival in ischemic hearts, at least in part, by enhancing NF-κB-dependent survival 
signaling.
4. Discussion
In the present study, we investigated whether FAK has a cardioprotective role in response to 
ischemia/reperfusion, a stimulus known to induce robust myocardial apoptosis and necrosis. 
We found that FAK activation is induced by Hypox/Reox and that depletion of FAK 
markedly exacerbates Hypox/Reox-induced cardiomyocyte cell death in vitro. Moreover, 
deletion of FAK in the adult myocardium resulted in significant increases in I/R-induced 
infarct size and cardiomyocyte apoptosis and a concomitant reduction in left ventricular 
function. Finally, our results suggest that NF-κB signaling may play a role in modulating 
FAK-dependent cardioprotection, since FAK inactivation blunted activation of NF-κB and 
reduced levels of the NF-κB target survival-genes, Bcl2 and Bcl-xl.
Although post-mitotic cells, like cardiomyocytes and neurons, are notoriously resistant to 
apoptosis, it is evident that apoptotic cardiomyocyte cell death plays a critical role in 
ischemia-induced myocardial damage. Notably, loss of function mutations in the so-called 
death receptor signaling components including Fas, Bid, or caspase 9, each lead to a 50–
60% reduction in infarct size [37–39]. Thus, the importance of defining pro-apoptotic and 
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pro-survival signals in cardiomyocytes is clear. Results from the current study confirm that 
FAK activity is important for survival of cultured neonatal rat cardiomyocytes exposed to 
ischemia [40] and our report is the first to show that FAK activation protects 
cardiomyocytes from I/R-induced apoptosis in vivo. The mechanism/s by which I/R 
stimulates FAK activation is not known. Integrin ligation is the main inducer of FAK 
phosphorylation, however the activity of FAK is also regulated by a number of G protein 
coupled receptors and growth factors (such as VEGF). Since many of these circulating 
factors are increased following I/R, they are likely to induce FAK activation in this setting 
[25,41]. Our demonstration that FAK inactivation resulted in enhanced cardiomyocyte 
apoptosis under stressed conditions, is consistent with previous studies implicating FAK in 
the survival of normal and cancerous cells [42]. Interestingly, FAK expression is up-
regulated in several solid tumors and FAK activity has been linked to tumor progression 
[13,42]. In light of our findings, it is tempting to speculate that enhanced FAK levels might 
function to protect tumor cells from their typically ischemic environment.
Our data suggest that FAK may regulate cardiomyocyte survival following I/R via activation 
of the NF-κB signaling cascade. Indeed, we observed decreased IκB phosphorylation, 
increased IκB protein levels, decreased NF-κB phosphorylation and lower levels of the NF-
κB-pro-survival target Bcl2 in the post I/R MFKO hearts in comparison to the genetic 
controls. Previous studies indicate that inactivation of FAK in either mouse embryo 
fibroblasts or kidney epithelial cells promotes TNFα-stimulated apoptosis by impairing RIP/
TRAF2 complex formation and blocking induction of NF-κB-dependent survival signals 
[29,30,43,44]. It is likely that a similar mechanism resulted in diminished I/R-dependent 
NF-κB activation in the MFKO hearts. It is important to note, however, that the function of 
NF-κB in the heart is controversial as it has been reported to induce both pro-survival and 
pro-apoptotic signals [32–34,45–50]. Thus, further experimentation is required to determine 
whether dampened NF-κB activation plays a causative role in the exacerbation of I/R-
induced apoptosis in MFKO hearts, or whether FAK may exert cardioprotective effects by 
additional mechanisms, such as, stimulation of PI3Kinase/AKT, Ras/ERK, and Cas/JNK 
signaling pathways, which promote survival in many cell types including cardiomyocytes 
[42,51,52].
An effect of FAK on cardiomyocyte apoptosis may have important implications on the role 
of FAK during heart failure. Although, apoptosis was originally thought to play a minor role 
in heart failure more recent evidence suggests that activators or inhibitors of this process 
influence this pathogenic process [53–55,19,20]. Our findings herein strongly support a 
critical cardioprotective role for FAK in response to I/R, however whether FAK plays a 
similar role in the transition from hypertrophy to heart failure is currently unclear. Although 
we previously showed that FAK inactivation leads to dilated cardiomyopathy after 
prolonged TAC, we found comparable (but limited) apoptosis following TAC in the genetic 
control and MFKO hearts (less than 0.03% TUNEL positive cells/condition) [18]. As 
quantifying differences at these low levels is technically challenging, it is possible that we 
missed a slight but significant difference in apoptosis in our previous studies. Importantly, 
recent data suggest that even very low rates of cardiac myocyte apoptosis (2–6 fold over 
control) are sufficient over time to cause a lethal dilated cardiomyopathy [56]. In light of our 
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new findings, it will be of future interest to determine whether anti-apoptotic treatments will 
halt the rapid progression to dilated cardiomyopathy in banded MFKO hearts.
In conclusion, using loss of function experiments, we have demonstrated that FAK is not 
necessary for myocyte survival or function in the adult myocardium. However, the absence 
of FAK in the myocardium exacerbates I/R-dependent apoptosis. Since the toggling between 
pro-survival and pro-apoptotic signals remains central to preventing irreversible damage to 
the heart [9], it will be of future interest to determine whether spatial-temporal activation of 
FAK can salvage “at risk” myocytes in the ischemic heart.
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Hypoxia/reperfusion-induced cell death is enhanced in FAK null cardiomyocytes. (A) left 
panel: cultured ventricular cardiomyocytes obtained from embryonic (E17.5) FAK−/−/
βMHCgfp and littermate control FAK+/+/βMHCgfp mice exhibit comparable sarcomeric actin 
(red) organization (20× power). Middle and right panels: representative images of viable 
FAK+/+/βMHCgfp and FAK−/−/βMHCgfp cardiomyocytes after exposure to normoxia or 
hypoxia/re-oxygenation (Hypox/Reox) as described in the Material and methods section. 
(10× power). (B) Viable cardiomyocytes following Hypox/Reox were expressed as a 
percentage of total viable cells in parallel normoxia cultures (n= 6 experiments in which 50–
300 cells were counted per experiment per condition). (C) Cultured rat neonatal (P0) 
cardiomyocytes were exposed to normoxia for 2.5 h or Hypox/Reox for 2 h and 15 min or 2 
h and 30 min and FAK activity was assessed by immunoblotting with an anti pY397-FAK 
antibody. Total FAK is shown as a loading control. (Right panel) Densitometric 
quantification is shown and data are expressed as mean ± SEM (n=3–4).
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Inactivation of FAK in the adult myocardium exacerbates I/R-induced myocardial 
infarction. MFKO and genetic control mice were subjected to I/R and injected with Evan’s 
blue dye to delineate the perfused regions and area at risk (AR) as described in the Materials 
and methods section. 24 h post I/R the myocardial tissue was harvested and stained with 
TTC. (A) The red area indicates the viable cardiac tissue while the white indicates the 
infarct in these representative sections. (B, C) Quantification of relative area at risk and the 
ratios of the infarct size to area at risk. Data are expressed as means±SEM (n=4–6).
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I/R-induced apoptosis is enhanced in MFKO hearts. Genetic control and MFKO mice were 
subjected to I/R as described above. Hearts were sectioned and processed for TUNEL 
labeling (red) and troponin T IHC (green) to detect DNA strand breaks in apoptotic 
cardiomyocytes. (A, B) Representative images from the region of the left ventricle 
juxtaposed to the infarct area in the control and MFKO hearts. (C) Quantification of 
apoptotic cardiomyocyte nuclei counted in the defined left ventricular area. Data are 
expressed as means±SEM (n=4).
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NF-κB activation is impaired in MFKO hearts in response to I/R. (A) Cardiac lysates 
procured from control and MFKO heart sections 24 h following I/R were analyzed by 
Western analysis using the indicated antibodies. (B) Densitometric quantification (n=3–4) is 
shown and data are expressed as mean percent change from control values±SEM. (C) 
Isolated RNAs from control and MFKO heart sections 24 h following I/R were subjected to 
semi-quantitative RT-PCR for Bcl2 and Bcl-xl. Message levels were normalized to 18S. (D) 
Cardiac tissue lysates from control and MFKO heart sections 24 h following I/R injury were 
immunoblotted for Bcl2 and Bcl-xl. ERK1/2 is shown as a loading control. (E) 
Densitometric quantification (n=3–4) is shown and data are expressed as mean percent 
change from control values±SEM.
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Table 1
Baseline echocardiographic analysis of control and MFKO mice
Parameters Genetic control MFKO
LVEdD (mm) 4.0±0.3 3.9±0.2
LVEsD (mm) 2.8±0.2 2.6±0.4
LVPWTd (mm) 0.9±0.1 0.8±0.1
LVPWTs (mm) 1.2±0.04 1.1±0.1
IVSd (mm) 1.3±0.1 1.1±0.2
IVSs (mm) 1.6±0.1 1.6±0.1
FS (%) 30.2±3.4 34.3±6.6
EF (%) 57.7±5.3 63±9.0
HR (bpm) 543±6 556±16
EF, ejection fraction; FS, fractional shortening; HR, heart rate; IVSd, interventricular septal thickness during diastole; IVSs, interventricular septal 
thickness during systole; LVEdD, left ventricular end diastolic diameter; LVEsD, left ventricular end systolic diameter; LVPWTd, left ventricular 
posterior wall thickness during diastole; and LVPWTS, left ventricular posterior wall thickness during systole.
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